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Abstract
Background. Outside of pregnancy, anti-glomerular basement membrane (GBM) antibody disease
is associated with signiﬁcant morbidity and mortality. However, there is limited knowledge regarding de novo anti-GBM disease in pregnancy.
Methods. A systematic review was performed to identify maternal, pregnancy and fetal outcomes
in de novo anti-GBM disease in pregnancy. Studies were selected from PubMed, EMBASE, Cochrane
Library databases and conference proceedings, without language restriction.
Results. Data from eight patients were derived from seven case reports and one unpublished case.
Most (6/8) patients presented after the ﬁrst trimester. During pregnancy, acute kidney injury (5/8),
anemia (5/8), hematuria (8/8) and proteinuria (8/8) were common. When hemodialysis was
required antepartum (5/8), renal function recovery to independence of renal replacement was
unlikely (2/5). While pulmonary involvement was common (5/8), no permanent damage was reported (0/8). The majority of cases ended in live births (6/8) although prematurity (6/6), intrauterine
growth restriction (2/6), small for gestational age (4/6) and complications of prematurity (1/6) were
common. When anti-GBM levels were tested in the living newborn, they were detectable (2/5), but
no newborn renal or lung disease was reported (0/6). Complications in pregnancy included gestational diabetes (3/8), hyperemesis gravidarum (2/8) and preeclampsia (2/8).
Conclusions. Live births can be achieved in de novo anti-GBM disease in pregnancy, but are
commonly associated with adverse maternal, pregnancy and fetal outcomes. Only with awareness
of common presentations, and management strategies can outcomes be optimized.
Keywords: anti-GBM; Goodpasture’s disease; placenta; pregnancy; vasculitis

Introduction
Anti-glomerular basement membrane (anti-GBM) antibody disease commonly leads to rapidly progressive glomerulonephritis (RPGN) [1, 2], end-stage kidney disease and
death [3]. Named eponymously for its discoverer in 1919
[4], Goodpasture’s syndrome consists of pulmonary hemorrhage and glomerulonephritis [5] caused by an autoantibody to alveolar and glomerular basement membrane
antigens [6].
Acute kidney injury (AKI) occurs in ∼1:15 000–1:20 000
pregnancies [7] and is associated with adverse maternal
and fetal outcomes. A number of etiologies are well established for obstetric AKI [8], but there is limited knowledge
regarding de novo glomerulonephritis, and in particular

de novo Goodpasture’s disease in pregnancy. Given the
implications of systemic vasculitis and its management in
maternal and fetal outcomes, literature on this topic is
essential.
We performed a systematic review of de novo anti-GBM
disease in pregnancy, reporting on clinical presentation,
management and pregnancy outcomes.

Methods
Search strategy and selection criteria
Electronic databases (PubMed, EMBASE and the Cochrane
Library) were searched up to 20 April 2014. Conference
abstracts (American Society of Nephrology 2003–2013,
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European Renal Association 2002–2013) were searched.
The search terms were ‘anti-GBM,’ ‘Glomerular basement
membrane,’ ‘pregnancy,’ ‘gestation,’ ‘Goodpasture’s disease,’
‘Goodpasture’s syndrome’. There were no restrictions on language, publication form or study type.
Studies and case reports were included if they met the
following criteria: (i) Patient was pregnant during diagnosis
or management of de novo anti-GBM disease. (ii) Anti-GBM
disease was conﬁrmed by positive anti-GBM antibody, renal
biopsy ﬁndings considered diagnostic for anti-GBM disease,
or both.
Data extraction and quality assessment

Data synthesis and analysis
Patient characteristics including maternal and gestational
age, obstetric history (gravidity and parity), and medical/
surgical history were collected. Clinical, laboratory and
radiologic features at presentation were recorded. Chest
imaging was recorded when available. When renal biopsy
was performed, the timing relative to pregnancy, and
whether it was diagnostic for anti-GBM disease was recorded. Information regarding immunosuppressive management was collected.
Maternal outcomes included antepartum and postpartum (i) renal function, deﬁned by serum creatinine, creatinine clearance or the need for renal replacement
therapy, (ii) lung function, deﬁned by the presence of
cough, dyspnea, hemoptysis or the result of radiologic
imaging (chest X-ray, ventilation-perfusion scan or pulmonary function tests). Pregnancy outcomes included (i) vaginal
versus cesarean section delivery, (ii) presence of pregnancyrelated complications, such as placenta praevia or abruptio,
hyperemesis gravidarum, gestational diabetes, gestational
hypertension or preeclampsia. Fetal outcomes included
(i) gestational age at birth, (ii) intrauterine growth restriction or small for gestational age, (iii) live birth or non-live
birth (therapeutic abortion, miscarriage, stillborn), (iv)
presence of congenital abnormalities at birth, (v) newborn
anti-GBM antibodies, (vi) newborn kidney or lung disease.

Results
Selected studies
Of 160 initial study abstracts reviewed, 12 qualiﬁed for full
review (Figure 1). A total of seven case reports were identiﬁed that related to de novo anti-GBM disease in pregnancy. One case report was from the 2006 American
Society of Nephrology annual conference abstracts [9],
and was the ﬁrst of two cases from our research group.
When an additional case from our research group was
added, there were eight total case reports of de novo antiGBM disease in pregnancy.
Patient characteristics
Maternal age ranged from 19 to 34 (mean 27.3) years
(Table 1). Most women presented in the second trimester

Fig. 1. Flow and selection of studies through review. GBM, glomerular
basement membrane.

(6/8) with only the case of Deubner et al. presenting at 12
weeks gestation and the case of Yankowitz et al. being diagnosed 3 months prior to pregnancy. Most (5/8) women
had no prior pregnancies, two women had other living
children. Underlying renal disease (‘possible IgA nephropathy’) was found in only one woman [15], and underlying
hypertension only in London, 2013.
Investigations
Markedly elevated serum creatinine was reported in 5/8
cases (Table 2), and anemia in all cases that reported a
serum hemoglobin (5/5). When reported, serum anti-GBM
titer was elevated at presentation (6/7). Urinalysis consistently showed hematuria (6/6) and proteinuria (6/6). Urine
microscopy conﬁrmed red blood cells (rbc) (6/6) but only
rarely revealed dysmorphic rbc (1/6) or cellular casts (1/6).
When performed, chest X-ray commonly (3/4) found evidence of parenchymal disease suggestive of pulmonary
hemorrhage. Renal biopsy was performed in most (7/8)
cases, once pre-pregnancy and equally frequently during
(3/7) and after pregnancy (3/7). Every kidney biopsy performed was diagnostic for anti-GBM disease (7/7).
Immunosuppression
Immunosuppressive therapy was used during pregnancy
in half (4/8) of the cases (Table 1). All immunosuppression
regimes included corticosteroids (8/8). Cyclophosphamide
exposure occurred during pregnancy in a minority of cases
(2/8) and was delayed to the post-partum period in three
cases. All patients received plasmapheresis during their
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One investigator (B.T.) twice used the search strategy to identify potentially relevant articles. Full reports of potentially
relevant studies were obtained and each was reviewed using
predeﬁned eligibility criteria. Data were abstracted for study
and patient characteristics, management strategy as well as
maternal, fetal and pregnancy outcome assessment.

De novo anti-GBM disease in pregnancy
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Table 1. Patient characteristics and immunosuppressive management of de novo anti-GBM disease in pregnancy
Nillsen
[10]

28
3 months
pre-pregnancy
G0 P0

Deubner
[12]

Al-Harbi [13]

Vasiliou
[14]

Nair [15]

Joseph [9]

London 2013

21
12

30
28

34
18

23
13

33
15

30
25

G0 P0

G7 P7

G1 P0

G0 P0

G0 P0

G2 P1

Possible IgA
nephropathy

HTN

Pre

Post

During

During

Post

During

During

(+)

(+)

(+)

(+)

(+)

(+)

(+)

(+)
(+) (n = 5)
(−)
PO CYC and PRED
continued in
pregnancy

(+)
(+) (n = NR)
(−)
None

(−)
(+) (n = NR)
(−)
Post-partum
management NR

(−)
(+) (n = 6)
(+)
None

(+)
(+) (n = 14)
(−)
None

(−)
(+) (n = 20)
(+)
Low-dose
ASA

(+)
(+) (n = 32)
(+)
Azathioprine post-3
IV CYC doses, 32
weeks gestation

ASA, acetylsalicylic acid; CYC, cyclophosphamide; HTN, hypertension; IV, intravenous; NR, not reported; PCOS, polycystic ovarian syndrome; PO, per oral;
PRED, prednisone.

Table 2. Investigations in patients with de novo anti-GBM disease in pregnancy

Nillsen [10]

Yankowitz [11]

Laboratory investigations at presentation
Creatinine (µmol/L)
NR
(CrCl = 198 mL/min)
Hemoglobin (g/dL)
NR
NR
Anti-GBM antibody
NR
(+)
Urinalysis

Al-Harbi [13] Vasiliou [14]

Joseph
Nair [15] [9]

London 2013

97
NR
12 U/mL
(‘borderline’)
NR

1217
6.6
(−)

1306
7.8
(+)

318
7.3
(+)

1130
5.9
(+)

(1+)HEM, (1+)
PRO
Dysmorphic
rbc, no casts

NR

1132
6.7
(+)

(1+)HEM,
(1+)PRO
NR

NR

5-6 wbc/HPF,
15–20 rbc/HPF

(3+)HEM,
(2+)PRO
>25 rbc/HPF,
no casts

NR

0.196

3.2

NR

NR

(+)HEM
(+)PRO
0–2
Rbc,
wbc/HPF Cellular
++ rbc/
casts
HPF
no casts
NR
NR

NR

CXR: ‘Bilateral
interstitial/nodular
inﬁltrates’

NR

CXR:
‘Congested
lungs’

NR

NR

Normal

Renal biopsy: performed
Timing (pre-pregnancy,
during or post-partum)

(+)
Post

(+)
Pre

(+)
Post

(+)
Post

(+)
During (18
weeks)

Diagnostic of anti-GBM
disease
Crescents (±, %)

(+)

(+)

(+)

(+)

(+)

(+)
During
(14
weeks)
(+)

(+)
During
(15
weeks)
(+)

(+),
‘advanced’

(+), NR

(+), 100%

(+), 100%

(+), 80%

(+), 60%

(+),
100%

Urine microscopy

24-h urine protein
quantiﬁcation (g/day)
Chest imaging

(3+)HEM, (2+)PRO

Deubner [12]

>3.0 g/L PRO
Large Blood
>100 rbc/HPF
<10 wbc/HPF,
granular casts
0.91
CXR: ‘Congested’
VQ scan:
‘suggestive of
pulmonary
hemorrhage’
(−)

CXR, chest X-ray; g, grams; HEM, hematuria; HPF, high powered ﬁeld; mL, milliliter; L, liter; NR, not reported; PRO, proteinuria; rbc, red blood cell; U, units;
VQ, ventilation-perfusion scan; wbc, white blood cell.

treatment course, but the number of treatments varied
dramatically (range 5–32). Azathioprine was used in the
absence of cyclophosphamide induction in two cases.

requiring hemodialysis, one after a therapeutic abortion at
15 weeks and the other after delivery at 26 weeks. While
many (5/8) women presented with potential pulmonary
hemorrhage, none were reported to have any permanent
pulmonary disease.

Outcomes: maternal
Most (7/8) women required hemodialysis during their clinical course, with most (5/8) requiring hemodialysis during
pregnancy (Table 3). Two women recovered renal function
following termination of pregnancy to the point of not

Outcomes: pregnancy
Vaginal and cesarean section delivery were equally performed for live births (3/6 for both) (Table 3). Gestational
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Patient characteristics
Maternal age (years)
19
Gestational age
19
(weeks) at presentation
Previous obstetric
G0 P0
history (gravida/parity)
Relevant past medical
history
Immunosuppressive management
Timing (prePost
pregnancy, during or
post-partum)
Induction:
(+)
corticosteroids
Cyclophosphamide
(+)
Plasmapharesis
(+) (n = NR)
Azathioprine
(−)
Other
None

Yankowitz [11]
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Table 3. Maternal, fetal and pregnancy-associated outcomes in de novo anti-GBM disease in pregnancy

Outcomes: maternal
Renal:
antepartum
Post-partum
Lung:
Antepartum

Yankowitz [11]

Deubner [12]

Al-Harbi [13]

Vasiliou [14]

Nair [15]

Joseph
[9]

Normal

Normal

RPGN, daily
HD

RPGN, daily HD

RPGN, daily HD

Normal

HD

Partial renal
recovery
‘Hemoptysis’
‘cough’

RPGN,
alternate day
HD
Full renal
recovery
‘Cough’
‘Dyspnea’

RPGN,
daily HD

RPGN,
HD, RTx
Normal

Proteinuria
hematuria,
mild RF
HD, RTx

HD, RTx

HD

Normal

Normal

Normal

Normal

Cough, dyspnea,
VQ: ‘pulmonary
hemorrhage’
Normal

London 2013

‘Hemoptysis’
‘Dyspnea’

Normal

Normal

Normal

Normal

‘Dyspnea’,
CXR:
‘Congested’
Normal

V
(−)

C
(−)

V
PEC

C
(−)

C
GDM, PEC

V
HG

V
GDM, HG,
PCP

V
GDM, HG

(−)(SB)
28

(+)
37

(+)
35

(+)
34

(+)a
26.5

(−)(TA)
15

(+)
35

(+)
35

NR

(−)

NR

NR

(+)

NR

(+)

(−)

NR

(−)

NR

(+)

(+)

NR

(+)

(+)

NR

(−)

NR

(−)

(+)

NR

(−)

(−)

NR

NR

(−)

(−)

(−)

NR

(+)

(+)

NR

(−)

(−)

(−)

(−)

NR

(−)

(−)

CXR, chest X-ray; GDM, gestational diabetes mellitus; HD, hemodialysis; HG, hyperemesis gravidarum; NR, not reported; PCP, Pneumocystis carinii
pneumonia; PEC, preeclampsia; RPGN, rapidly progressive glomerulonephritis; RTx, renal transplantation; SB, stillborn; TA, therapeutic abortion;
VQ, ventilation-perfusion lung scan.
a
Livebirth in Vasiliou born with ‘massive intraventricular hemorrhage,’ developed neurodevelopmental delay, visual dysfunction, failure to thrive.

diabetes (3/8), preeclampsia (2/8), hyperemesis gravidarum (2/8) and severe infections (1/8) were reported complications in pregnancy.
Outcomes: fetal
Most (6/8) cases resulted in singleton live births (Table 3).
However, all live births were premature (6/6 live births),
with severe prematurity (26.5 weeks) in one case. When
reported, intrauterine growth restriction (3/4) and small
for gestational age (4/5) were common. One infant had
severe complications of prematurity with intraventricular
and intraparenchymal hemorrhage, and at 1 year continued to have neurocognitive delay [14]. Anti-GBM antibodies were measured (5/8) and present in only two
newborns. However, no kidney or lung disease was reported in any of the newborns.

Discussion
Our study conﬁrms that maternal, pregnancy and fetal
outcomes in de novo anti-GBM disease in pregnancy are
poor, comparable to systemic lupus erythematosus (SLE).
From a maternal perspective, the chance of renal recovery
is very low. Interestingly, one dialysis-dependent patient
had complete recovery of renal function with aggressive
treatment and therapeutic abortion at 15 weeks compared with all other patients who reached ESRD or had
severe renal dysfunction despite coming off hemodialysis.
Pregnancy may worsen the clinical course in SLE patients
[16], and therapeutic abortion may be recommended in

severe circumstances [17]. This may suggest that similar
to SLE patients, pregnancy may worsen the clinical
course. Pregnancy complications were also high in de
novo anti-GBM disease treated with immunosuppression,
with high rates of gestational diabetes (3/8), preeclampsia
(2/8), hyperemesis gravidarum (2/8) and serious infection
(1/8). Finally, fetal complications in de novo anti-GBM
disease in pregnancy are high, with prematurity (6/6 live
births), intrauterine growth restriction (3/4), small for gestational age (4/5) and congenital abnormalities (2/6 live
births). Fetal demise or severe adverse fetal outcomes
were present in three of eight. While live births are possible in de novo anti-GBM disease (6/8), understanding the
risks of renal biopsy, immunosuppression and hemodialysis are crucial to fully inform the mother of her optimal
management decisions.
Renal biopsy during pregnancy was performed in only a
minority (3/8) of cases (Table 2). While initial reports of
antepartum renal biopsies were associated with high
rates of bleeding complications [18], this was confounded
by concurrent hypertension and preeclampsia, conditions
in which a bleeding complication is well recognized [19].
Indeed, more recent trials indicate similar complication
rates between pregnant and non-pregnant patients [20,
21]. Furthermore, renal biopsy results can signiﬁcantly
alter management decisions. In Vasiliou et al. and Joseph
et al. cases, renal biopsy revealed >50% crescentic glomeruli [14] suggesting renal recovery was quite unlikely
[22]. Under such circumstances, immunosuppression with
the potentially teratogenic cyclophosphamide could be
avoided if the patient does not have persisting pulmonary
hemorrhage. Nair et al. [15] renal biopsy results may have
informed patient counseling and decision-making. Thus,
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Post-partum
Outcomes: pregnancy
Delivery method
Pregnancyrelated
complications
Outcomes: fetal
Livebirth
Delivery date
(weeks gestation)
Intrauterine
growth restriction
Small for
gestational age
Complication of
prematurity
Newborn antiGBM antibodies
Newborn kidney
or lung disease

Nillsen
[10]

De novo anti-GBM disease in pregnancy

thrombocytopenia [46, 47] and leucopenia [48] in newborns. Thus, judicious use of azathioprine, with close monitoring for associated side effects, may be appropriate to
optimize maternal and fetal outcomes.
In non-pregnant patients with incident Goodpasture’s
disease, plasmapheresis may be indicated in the presence
of pulmonary hemorrhage [49] or AKI with a reasonable
likelihood of recovery [27]. Typically, daily or alternate
daily plasma exchanges with albumin are performed for
2–3 weeks [22, 26, 49], unless ongoing bleeding is present,
in which case fresh frozen plasma may be used to replace
blood clotting factors [25]. In combination with immunosuppression, plasmapheresis reduces titers of anti-GBM
antibodies. Most mothers in our series (6/8) had detectable anti-GBM antibodies during pregnancy, and the levels
were signiﬁcantly lowered with plasmapheresis. Plasmapheresis is generally considered safe in pregnancy [50].
There is strong evidence that anti-GBM antibodies bind
human placental antigens [51]; however, the clinical impact
of this is controversial. Deubner et al. [12] hypothesized a
protective effect of non-speciﬁc placental binding of antiGBM antibodies, leading to decreased transfer to the fetus,
and decreased total anti-GBM antibody maternal levels.
Joseph et al. [9] performed placental testing of IgG antibodies and showed diffuse binding of IgG antibodies; unfortunately, speciﬁc testing for anti-GBM antibodies could
not be done. They postulated that anti-GBM binding to
placenta may increase the risk of placental insufﬁciency
and ultimately preeclampsia if not treated aggressively
similar to Vasillou et al. [14]. Anti-GBM antibodies are IgG
antibodies and as such are actively transported across the
placenta via placental transporters; therefore, it is expected that the fetus would be exposed to all maternal
IgG antibodies including anti-GBM antibodies.
Newborn anti-GBM antibody levels were commonly
negative in our series (3/5) [12–14]. However, maternal
anti-GBM levels in these three cases were negative [13],
‘decreasing,’ [14] or ‘borderline’ when measured closer to
delivery [12]. To determine whether anti-GBM antibodies
transfer across the placenta, simultaneous collection of
maternal, neonatal and cord blood must be performed
at a time when maternal anti-GBM titers are detectable.
Simultaneous evaluation at delivery conﬁrmed anti-GBM
titers equivalent (mother = 4.3 U/mL, newborn = 6.5 U/mL,
cord blood = 5.8 U/mL) [9] or lower in the mother (London,
2013: mother < 2.5 U/mL, newborn = 9.0 U/mL). Thus, antiGBM antibodies cross the placenta, and it is unlikely that the
placenta plays a protective role. While there remain no reported cases of newborn anti-GBM disease, this provides only
some reassurance given only six described live births from
mothers with de novo anti-GBM disease in pregnancy
(Table 3). Moreover, transplacental antibody transmission has
been linked to neonatal pulmonary-renal syndrome from
myeloperoxidase-ANCA antibodies [52, 53], and neonatal
lupus erythematosus from a variety of lupus antibodies [54].
Literature regarding hemodialysis in pregnancy has expanded since the ﬁrst report of de novo anti-GBM disease
in pregnancy, in 1986 [10]. Comprehensive reviews of this
topic are available [55, 56]. Adverse maternal and fetal outcomes in women with end-stage kidney disease on hemodialysis are common, including maternal hypertension,
anemia and preeclampsia, and fetal intrauterine growth restriction, polyhydramnios, prematurity and death [57, 58].
Ultimately, great attention to calcium and phosphate
balance, nutrition, iron supplementation and anemia, dialysis duration, target weight, and blood pressure is required
[55, 56], to optimize outcomes.
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renal biopsy during pregnancy should be performed with
caution, but ultimately should be considered when it
offers the opportunity to make a diagnosis other than
severe preeclampsia (far) from term [23].
The goal of treatment in de novo Goodpasture’s disease
in pregnancy must be to induce remission, in light of the
signiﬁcant maternal and fetal morbidity and mortality associated with uncontrolled vasculitis [17, 24]. Induction
therapy for de novo Goodpasture’s disease may require a
combination of corticosteroid with oral or intravenous
cyclophosphamide (CYC), followed by maintenance immunosuppression with azathioprine [25–27]. Systemic
corticosteroids are generally considered low risk for
teratogenicity, with historical links to cleft palate [28, 29]
although this association is unclear [30]. Reported associations with adverse pregnancy outcomes [30, 31] are difﬁcult to disentangle from the effects of the disorder for
which the pregnant women is being treated [28]. Of cases
in which immunosuppression was started in pregnancy
with a goal of a live birth, all received a high dose then
tapering doses of corticosteroids. Corticosteroids increase
the risk of gestational diabetes [32], a complication seen
often in our review (3/8) [9, 11, 14]. Thus, it is important
to monitor for adverse effects of corticosteroids while
simultaneously inducing disease remission, particularly
pulmonary hemorrhage, as a primary goal.
The Food and Drug Administration (FDA) has evaluated
cyclophosphamide as Category D, indicating positive evidence of human fetal risk, but potential beneﬁts may
warrant use of the drug in pregnant women despite potential risks [33]. Use of cyclophosphamide during the ﬁrst
trimester, during organogenesis, has been associated
with malformation [34, 35] and miscarriages [35]. Growth
retardation, suppression of fetal hematopoiesis and impaired neurological development have been reported with
use later in pregnancy in the second and third trimesters
[34, 35]. Cyclophosphamide use during pregnancy has
been associated with adverse outcomes in SLE [36–38].
Cyclophosphamide exposure increases long-term risk of
malignancies in patients treated with the drug [39] and
papillary thyroid cancer and neuroblastoma was reported
in a child exposed in utero to cyclophosphamide [40]. It is
difﬁcult to extrapolate the effects of cyclophosphamide
during pregnancy in de novo anti-GBM disease in pregnancy from our study, since only one of our cases was
exposed. Potential beneﬁts may warrant use of the drug in
select pregnant women with severe disease despite the
known potential fetal risks. The decision whether or not to
initiate cyclophosphamide should be made after considering the stage of pregnancy, weighing the relative efﬁcacy
of alternative therapies, and counseling of patients regarding
maternal and fetal risks.
The use of azathioprine has been established as safe
throughout pregnancy in a variety of clinical settings;
transplant, inﬂammatory bowel and SLE literature [41, 42].
A meta-analysis did not ﬁnd an association between maternal thiopurine exposure for inﬂammatory bowel disease
and congenital defects [43]. Lower birth weight and higher
prematurity rate have been reported but may be an effect
of maternal underlying disease [44]. While ineffective for induction of severe anti-GBM disease, use of azathioprine may
be appropriate in mild de novo anti-GBM disease in pregnancy. Moreover, use of azathioprine in combination with
plasmapheresis may permit deferral of cyclophosphamide
use until after pregnancy. Azathioprine-associated bone
marrow suppression should be monitored [45]. Maternal
thiopurine use has been associated with anemia and
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Pregnancies complicated by vasculitis, the need for hemodialysis and immunosuppression require special expertise
using a multidisciplinary approach to optimize maternal,
pregnancy and fetal outcomes. Input from high risk obstetrics, dietician, social work, clinical pharmacy, neonatology,
nephrology, pediatrics and anesthesia are all beneﬁcial.
The need for this expertise necessitates patient admission
to an academic hospital with the resources to facilitate
management.
In conclusion, de novo anti-GBM disease in pregnancy is
associated with poor maternal and fetal outcomes. Given
the complexity of issues and decisions surrounding renal
biopsy and immunosuppression, a multidisciplinary team
is needed to provide comprehensive patient counseling
and to optimize maternal, pregnancy and fetal outcomes.
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